

FOR IMMEDIATE RELEASE

## AQUARIUS SURGICAL TECHNOLOGIES REPORTS RESULTS OF OPERATIONS FOR THE PERIOD ENDING SEPTEMBER 30, 2017

Halifax, Nova Scotia, November 30, 2017; AQUARIUS SURGICAL TECHNOLOGIES INC. (ASTI – CSE) (“the Corporation”) today reports the results of operations for the three month and six month periods ended September 30, 2017. All amounts referenced herein are in Canadian dollars.

The following table shows the results for the comparable periods:

	Three Months Ended		Six Months Ended	
	Sep 30,2017	Sep 30,2016	Sep 30,2017	Sep 30,2016
	\$	\$	\$	\$
<b>Sales</b>	<b>201,265</b>	-	<b>352,872</b>	-
<b>Cost of sales (Note 6)</b>	<b>187,620</b>	-	<b>296,219</b>	-
<b>Gross Margin</b>	<b>13,645</b>	-	<b>56,653</b>	-
<b>Expenses</b>				
General and administrative (Note 14)	335,876	36,670	682,935	41,888
Bank charges and interest	2,203	512	3,865	1,013
Amortization (Notes 7 and 8)	122,632	23	244,946	47
	<b>460,711</b>	<b>37,205</b>	<b>931,746</b>	<b>42,948</b>
<b>Net loss before other items</b>	<b>(447,066)</b>	<b>(37,205)</b>	<b>(875,093)</b>	<b>(42,948)</b>
<b>Other items:</b>				
Royalty income	915	3,086	2,592	5,158
<b>Total comprehensive loss</b>	<b>(446,151)</b>	<b>(34,119)</b>	<b>(872,501)</b>	<b>(37,790)</b>
<b>Loss per share, basic and diluted</b>	<b>(\$0.025)</b>	<b>(\$0.006)</b>	<b>(\$0.050)</b>	<b>(\$0.007)</b>
Weighted average number of shares outstanding (Notes 11 and 15)	18,141,430	5,397,411	17,484,880	5,397,411

The results in the current year include the operations of Surgical Lasers Inc. which was acquired effective from March 1, 2017. The per share amounts for the prior year have been adjusted to reflect the consolidation of the Corporations shares on a 1 for 20 basis effective February 24, 2017

Said Gordon Willox, Managing Director of Surgical Lasers Inc.: “The Sales for the Quarter reflect the comparatively long cycle between introduction of a new technology in the medical sector to the point where it is readily accepted by surgeons and medical practitioners without extensive preliminary testing. In the case of the Surgical Lasers Inc. flagship product, the MP200 Series laser, which is used in benign prostatic hyperplasia surgery, the cycle generally takes about six months between the point where a practitioner first starts trials on a MP200 laser and when he is in a position to reorganize his practice and will commit to purchasing a unit. We have now, in most cases, reached the point where the trial periods are converting into firm sales. In addition, the Company is seeing strong demand for its Holmium Laser units, used in lithotripsy procedures. We are looking towards a significant increase in Sales for the Third Quarter of the current fiscal period, to December 31, 2017, reflecting growing sales of both these laser product ranges, together with related single-use fibers.”

The Corporation has filed its unaudited consolidated financial statements and management discussion and analysis for the second quarter ended September 30, 2017. Both are available under the Corporation's profile on SEDAR at [www.sedar.com](http://www.sedar.com). These and other corporate filings are also available on the CSE website [www.thecse.com](http://www.thecse.com) under the Corporation's symbol “ASTI”.

For further information, please contact:

N Gary Van Nest  
Acting Chief Executive Officer  
(647) 308-0685  
Email: [gary@sinaltainvestments.com](mailto:gary@sinaltainvestments.com)

*The Canadian Securities Exchange has neither approved nor disapproved of the information contained in this release. This Media Release may contain forward-looking statements, which reflect the Corporation's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ from those projected herein and depend on a number of factors including the success of the Corporation's sales strategies.*